Aflibercept - Biologic Drug Details

Summary for aflibercept

Tradenames:	2
High Confidence Patents:	13
Applicants:	1
BLAs:	2
Suppliers: see list	2
Recent Clinical Trials:	See clinical trials for aflibercept
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for aflibercept

Recent Clinical Trials for aflibercept

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
H. Lee Moffitt Cancer Center and Research Institute	Phase 2
Genzyme, a Sanofi Company	Phase 2
Aerie Pharmaceuticals	Phase 1/Phase 2

See all aflibercept clinical trials

Recent Litigation for aflibercept

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.	2024-09-24
Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.	2024-06-20
Novartis Pharma AG v. Regeneron Pharmaceuticals, Inc.	2023-01-05

See all aflibercept litigation

PTAB Litigation

Petitioner	Date
Regeneron Pharmaceuticals, Inc. et al.	2021-04-16
Regeneron Pharmaceuticals, Inc.	2020-07-16
Regeneron Pharmaceuticals, Inc. et al.	2020-07-16

See all aflibercept litigation

Pharmacology for aflibercept

Mechanism of Action	Vascular Endothelial Growth Factor Inhibitors
Established Pharmacologic Class	Vascular Endothelial Growth Factor Inhibitor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for aflibercept Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for aflibercept Derived from Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387		2037-03-28	Company disclosures
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387		2038-10-12	Company disclosures
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387		2039-04-29	Company disclosures
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387		2039-09-25	Company disclosures
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387		2040-01-10	Company disclosures
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387		2041-06-21	Company disclosures

3) Low Certainty: US Patents for aflibercept Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387		2032-05-15	Patent claims search
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387		2034-11-25	Patent claims search
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387		2036-04-22	Patent claims search
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387		2034-03-18	Patent claims search
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387		2036-04-22	Patent claims search
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387		2032-12-05	Patent claims search

International Patents for aflibercept

Country	Patent Number	Estimated Expiration
Spain	2354847
Spain	2237429
Russian Federation	2265661
Portugal	1183353
Poland	208247
Cyprus	1124265

Supplementary Protection Certificates for aflibercept

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
SPC/GB13/028	United Kingdom		PRODUCT NAME: AFLIBERCEPT; REGISTERED: UK EU/1/12/797/001 20121122; UK EU/1/12/797/002 20121122
132013902154380	Italy		PRODUCT NAME: AFLIBERCEPT(EYLEA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/12/797/001-002, 20121122
122013000041	Germany		PRODUCT NAME: AFLIBERCEPT; REGISTRATION NO/DATE: EU/1/12/797/001-002 20121122
CR 2013 00020	Denmark		PRODUCT NAME: AFLIBERCEPT; REG. NO/DATE: EU/1/797/001-002 20121122
C300588	Netherlands		PRODUCT NAME: AFLIBERCEPT; REGISTRATION NO/DATE: EU/1/12/797/001-002 20121122
C201300026	Spain		PRODUCT NAME: AFLIBERCEPT; NATIONAL AUTHORISATION NUMBER: EU/1/12/797/001-002; DATE OF AUTHORISATION: 20121122; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/12/797/001-002; DATE OF FIRST AUTHORISATION IN EEA: 20121122